Myricetin

Interesting preclinical data for neuroprotection and metabolic health, but human clinical trials are extremely scarce. Low oral bioavailability is a significant limitation.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Myricetin inhibits amyloid-beta aggregation, reduces tau phosphorylation, and improves insulin sensitivity in animal models. It has broad antioxidant and anti-inflammatory activity. However, oral bioavailability is very low due to extensive first-pass metabolism, and human clinical trials are nearly nonexistent.

• Anti-amyloid and neuroprotective in preclinical models
• May improve insulin sensitivity in animal studies
• Broad antioxidant activity

No established supplemental dose. Dietary intake from berries, walnuts, and grapes is typically 1-10 mg daily.

• Limited data on isolated supplementation
• Potential GI effects
• May affect iron absorption

Limited safety data for isolated supplementation. May interact with CYP enzymes. Iron chelation potential.

Virtually all evidence is preclinical. Very poor oral bioavailability limits translation. Benefits from dietary sources may involve synergy with other food compounds.

• Longevity20
• Memory18